Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Public ClinicalTrials.gov record NCT06349642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Study identification
- NCT ID
- NCT06349642
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 324 participants
Conditions and interventions
Conditions
- Early Stage Triple-Negative Breast Carcinoma
- Metastatic Bladder Urothelial Carcinoma
- Metastatic Cervical Carcinoma
- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Colorectal Carcinoma
- Metastatic Endometrial Carcinoma
- Metastatic Esophageal Carcinoma
- Metastatic Liver Carcinoma
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Malignant Skin Neoplasm
- Metastatic Malignant Solid Neoplasm
- Resectable Lung Non-Small Cell Carcinoma
- Early Stage Lung Non-Small Cell Carcinoma
- Resectable Malignant Solid Neoplasm
- Resectable Triple-Negative Breast Carcinoma
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
- Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Recurrent Cervical Carcinoma
- Recurrent Colorectal Carcinoma
- Recurrent Endometrial Carcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Liver Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Recurrent Malignant Skin Neoplasm
- Recurrent Malignant Solid Neoplasm
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2024
- Primary completion
- Apr 30, 2027
- Completion
- Apr 30, 2027
- Last update posted
- Mar 11, 2026
2024 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona | Phoenix | Arizona | 85054 | Recruiting |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | Recruiting |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06349642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06349642 live on ClinicalTrials.gov.